Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
27 studies found for:    blinatumomab
Show Display Options
Rank Status Study
1 Active, not recruiting Phase 2 Trial of Blinatumomab in Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia
Condition: Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab
2 Not yet recruiting A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Blinatumomab
3 Recruiting Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Procedure: Hematopoietic Cell Transplantation
4 Active, not recruiting
Has Results
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: Blinatumomab
5 Active, not recruiting
Has Results
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Condition: Diffuse Large B-cell Lymphoma
Intervention: Drug: Blinatumomab
6 Active, not recruiting
Has Results
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: B-cell Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab
7 Completed
Has Results
Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL
Condition: Non-Hodgkin's Lymphoma, Relapsed
Intervention: Biological: Blinatumomab (MT103)
8 Active, not recruiting
Has Results
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
Condition: B-ALL
Intervention: Biological: Blinatumomab
9 Completed
Has Results
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: Blinatumomab (MT103)
10 Recruiting Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Condition: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Blinatumomab
11 Completed Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: blinatumomab
12 Active, not recruiting Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Condition: Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Drug: Standard of Care Chemotherapy
13 Recruiting Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Conditions: Leukemia;   Acute Lymphocytic Leukemia
Interventions: Drug: Blinatumomab;   Behavioral: Phone Calls
14 Recruiting Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL
Condition: Leukemia, Acute Lymphoblastic
Interventions: Drug: Blinatumomab;   Drug: Conventional Consolidation Chemotherapy
15 Not yet recruiting Study to Evaluate Safety and Efficacy of Blinatuomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
Condition: B-Cell Non Hodgkin Lymphoma
Interventions: Drug: Blinatumomab;   Drug: Investigator's Choice Chemotherapy
16 Not yet recruiting A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: blinatumomab
17 Not yet recruiting D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Dasatinib;   Drug: Blinatumomab
18 Recruiting Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Mediastinal Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions: Biological: Blinatumomab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
19 Available Expanded Access Protocol of Blinatumomab in Pediatric and Adolescent Subjects With Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Blinatumomab
20 Recruiting Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
Conditions: B Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Recurrent Adult Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: Blinatumomab;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Prednisone;   Drug: Vincristine Sulfate

   Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.